Arrayit Corporation (ARYC)

[Alyssa]

It would be worth a lot if the OvaDx ducks were all in a row and legitimate, but that remains a mystery since we haven't heard much about OvaDx in a few years. Is this the "major microarray technology product line" that Arrayit submitted to the FDA in 2018? And what is the status now? Unfortunately, we just don't know. With everything that has happened, one has to wonder if Mark's meeting with the FDA really happened, despite the photo of him standing right there at the FDA headquarters. One has to also wonder about the other tests in their pipeline, which tests are still mentioned in the ARYC website.

Here is an excerpt from an article written in 2013, which explains how the test would save women and billions of dollars in healthcare costs, and provide "$975 million" to Arrayit's revenue.

"It does not seem an exaggeration to say that the OvaDx® test would deliver a substantial benefit to ovarian cancer patients and to the nation by reducing costs in the healthcare system. Extrapolating information from the NCI and others, nearly 10 percent of adult women in the U.S. run an elevated risk of ovarian cancer and should be tested every five years, meaning that approximately 1.5 million tests should be conducted annually. At a $650-per-test price point, sales would total $975 million annually for Arrayit.

$975 million in testing could potentially reduce ovarian cancer deaths by more about 80 percent (based upon cumulative specificity modeling as noted above), meaning that running a 2.5-hour OvaDx® screen could save about 12,000 women’s lives each year and more than $3.1 billion in associated healthcare costs."

http://ca.finance.yahoo.com/news/could-arrayits-early-ovarian-cancer-140000271.html